Bacterial conjugation

ZyVersa Therapeutics Announces New Peer-Reviewed Publication Reinforcing the Rationale for Inhibiting ASC Specks with IC 100 to Attenuate Spread of Inflammation into Surrounding Tissues

Retrieved on: 
Wednesday, October 4, 2023
Heart, ASC, Tissue, MEFV, University, Microbiology, Inflammasome, Leonard M. Miller School of Medicine, AIM2, Serum, Associate professor, Neurosurgery, Traumatic brain injury, Bacterial conjugation, Brain, TBI, Inflammation, Research, CNS, EVS, Super Meat Boy, Seminal vesicles, Journal, Patient, Translational research, Invention, Mouse, Paper, Immunology, Therapy, Injury, Physiology, Pharmaceutical industry, Vaccine, Medication, Biophysics, Medicine

Marks the third publication in 2023 supporting the potential need to attenuate the spread of inflammation to surrounding tissues to minimize the potential for co-morbidities in certain diseases.

Key Points: 
  • Marks the third publication in 2023 supporting the potential need to attenuate the spread of inflammation to surrounding tissues to minimize the potential for co-morbidities in certain diseases.
  • ZyVersa is developing Inflammasome ASC Inhibitor IC 100 to inhibit multiple types of inflammasomes and their associated ASC specks that trigger damaging inflammation and its spread to surrounding tissues.
  • Data indicate that pyrin inflammasome-mediated inflammation induced by TBI contributes to cardiovascular co-morbidities through systemic release of proinflammatory mediators that activate AIM2 inflammasomes in the heart leading to damaging inflammation.
  • “A heightened systemic inflammatory response is often induced after TBI, but the underlying pathomechanisms that contribute to co-morbidities remain poorly understood.

Replay announces partnership between product company Syena and JURA Bio to advance T cell receptor NK therapies in cancer

Retrieved on: 
Thursday, September 21, 2023
KRAS, Antigen, DNA, Partnership, MD–PhD, Therapy, Blood, Doctor of Philosophy, Bacterial conjugation, Writing, MHC, Cancer, ML, Stanford University, Coronavirus Scientific Advisory Board, Microsoft, Addgene, Research, Monroe Dunaway Anderson, Harvard University, Haematopoietic system, Autoimmunity, TCR, Associate, MD Anderson Cancer Center, Chemistry, Genome, Patient, Machine learning, Melanoma, Engineering, Immune system, Autoimmune disease, Yale University, University, Physics, Biology, Entrepreneurship, Library, Synthetic biology, Prostate cancer, Pharmaceutical industry, Vaccine, Medical device, Replay, MD

This will be invaluable in helping Replay’s cell therapy product company Syena to advance novel TCR-NK therapies into the clinic.”

Key Points: 
  • This will be invaluable in helping Replay’s cell therapy product company Syena to advance novel TCR-NK therapies into the clinic.”
    “We’re thrilled to announce our first partnership with Replay and its product company Syena.
  • This partnership validates our approach of using synthesized human T cell repertoires to generate safe and effective libraries to discover antigen specific TCRs at scale,” said Elizabeth Wood, Ph.D., Founder & CEO, JURA Bio.
  • If the option is exercised, Replay and its cell therapy product company Syena will be responsible for global development and hold exclusive worldwide commercialization rights on all TCR-NK therapies resulting from the partnership.
  • Replay launched Syena, an oncology-focused product company, with The University of Texas MD Anderson Cancer Center in February 2023.

JURA Bio Announces Partnership With Replay Product Company Syena to Advance T Cell Receptor NK Therapies in Cancer

Retrieved on: 
Thursday, September 21, 2023
Research, Genetics, Clinical Trials, Stem Cells, Biotechnology, Health, Pharmaceutical, Science, Oncology, KRAS, Antigen, Partnership, MD–PhD, Therapy, Blood, Doctor of Philosophy, Bacterial conjugation, MHC, Cancer, ML, Stanford University, Coronavirus Scientific Advisory Board, Microsoft, Addgene, Multimedia, Monroe Dunaway Anderson, Harvard University, Haematopoietic system, Autoimmunity, TCR, Associate, MD Anderson Cancer Center, Chemistry, Genome, Patient, Machine learning, Melanoma, University, Engineering, Immune system, Autoimmune disease, Yale University, Physics, Biology, Entrepreneurship, Library, Synthetic biology, Prostate cancer, Pharmaceutical industry, Management, Vaccine, Medical device, Replay, MD

JURA Bio , a biotechnology company developing immune-based therapeutics using machine learning and synthetic biology, announced today a research collaboration with Syena, a cell therapy product company and subsidiary of Replay, a genome writing company, to develop T cell receptor (TCR) based therapies.

Key Points: 
  • JURA Bio , a biotechnology company developing immune-based therapeutics using machine learning and synthetic biology, announced today a research collaboration with Syena, a cell therapy product company and subsidiary of Replay, a genome writing company, to develop T cell receptor (TCR) based therapies.
  • Photographer: Maki Suzuki
    “We’re thrilled to announce our first partnership with Replay and its product company Syena.
  • If the option is exercised, Replay and its cell therapy product company Syena will be responsible for global development and hold exclusive worldwide commercialization rights on all TCR-NK therapies resulting from the partnership.
  • Replay launched Syena, an oncology-focused product company, with The University of Texas MD Anderson Cancer Center in February 2023.

Affimed Announces Acceptance of Abstracts at the 17th International Conference on Malignant Lymphoma (17-ICML)

Retrieved on: 
Friday, June 9, 2023
PTCL, Hodgkin lymphoma, Abstract, Peripheral T-cell lymphoma, ASH, REDIRECT, Affimer, Bacterial conjugation, Lymphoma, Cancer, Food and Drug Administration, NK, International Conference on Creationism, Poster, Patient, Samsung Medical Center, FDA, IND, Nanakaly Hospital for Hematology & Oncology, Conference, Food, Safety, Pharmaceutical industry, Medical imaging, Book

An additional encore oral presentation will show the final results of the phase 2 REDIRECT study with AFM13 monotherapy in a r/r PTCL patient population.

Key Points: 
  • An additional encore oral presentation will show the final results of the phase 2 REDIRECT study with AFM13 monotherapy in a r/r PTCL patient population.
  • Associated with the AFM13-induced cytotoxic activity was an increased functional activation status of AB-101 demonstrated through degranulation and IFN-γ production.
  • Importantly, in a mouse xenograft model, adoptive transfer of AB-101 in combination with AFM13 conferred tumor growth control.
  • The data of AFM13 in combination with the allogeneic, cryopreserved, off-the-shelf, cord blood-derived AB-101 NK cells demonstrate synergistic anti-tumor activity in vivo.

Nkarta Presents Preclinical Data Exploring Gene Knockout Strategies and Combination Agents with NK Cell-Based Therapies at the 2023 AACR Annual Meeting

Retrieved on: 
Monday, April 17, 2023
Rituximab, CRISPR, AACR, CD16, ADCC, CISH, Bacterial conjugation, Cancer, Head, NK, HL60, Doctor of Philosophy, Cetuximab, CAR, Immunoglobulin G, EGFR, CD62L, ADAM17, Vaccine

SOUTH SAN FRANCISCO, Calif., April 17, 2023 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat cancer, today announced the presentation of two preclinical data abstracts focused on its natural killer cell pipeline and proprietary manufacturing technology at the 2023 American Association of Cancer Research (AACR) Annual Meeting.

Key Points: 
  • ADAM17 KO NK cells maintain dramatically higher surface expression of CD16a and CD62L than control NK cells.
  • ADAM17 KO CD19 CAR NK cells demonstrate higher cytotoxicity compared to control NK cells against Raji tumor cells in the presence of rituximab (anti-CD20).
  • Furthermore, ADAM17/CISH/CBLB triple KO CD70 CAR NK cells have improved antitumor efficacy in vivo in an HL60 AML xenograft model.
  • These data support the further exploration of ADAM17 KO CAR NK cells for clinical application and to improve the efficacy of therapeutic antibodies in combination with the adoptive transfer of engineered NK cells.